And with the growth in the quarter of 10.5%, we now have rolling 12-month revenues approaching 7.4 billion.
And we have a rolling adjusted EBIT margin, which is flat compared to Q4 24. And it was 4.2%. And let's take a closer look on the revenues to the left. You see our net revenue development.
And as mentioned, we had growth in the quarter of 10.5%, and the growth was not fairly evenly distributed across our product areas.
Roughly 10% growth in Rx as well as in non-Rx. And we experience a continued solid demand for pharmaceutical products. Online, to the right. You see our gross margin, uh, we had a slight increase in the gross margin in Q1 compared to Q1 25. And the increase was the result of successfully executed campaigns as well as improved purchasing.
Our ambition is to have a fairly stable gross margin and with attractive prices, attract more and more people to buy pharmacy products online.
We had a strong operating profit in the quarter. We had an operating profit of 101 million. And the operating profit increased despite increased depreciations related to the new fulfillment center in Varberg, and the increase in operating profit was driven by increased net revenues as well as slightly higher gross margin, as mentioned, and continued good cost control.
Let's talk more about the cost; then, to the right, you see a breakdown of our operating costs. And as you can see, the depreciations as a percentage of revenues increased in Q1 as expected. And the increase was related to the new fulfillment center in Varberg that was opened last year, and depreciation started in Q4 last year.
If we then look on personnel costs and other operating costs and take those combined, these are fairly flat compared to a year ago. And we maintain good cost control, and as we've mentioned before, and worth mentioning again, the mix between personnel costs and other operating costs is also impacted by the usage of external staffing in our fulfillment centers.
We did not have any items affecting comparability in Q1.
We had a strong operating cash flow in Q1, and that was fairly stable compared to a year ago.
We had limited investments in Q1. The investments in Q1 2025 were related to the new fulfillment center in Varberg, which is now the platform. Investments are completed, and we expect this year to have significantly lower CapEx level compared to a year ago.
If we take a close look on the net working capital to the right, you can see that the inventory increased compared to a year ago, and the increase in inventory also impacted the inventory turnover rate somewhat, which is slightly lower, and the increase was noted.
The increase in inventory was primarily the result of increased inventory in Varberg. We have slightly lower return on capital employed in Q1 compared to a year ago. However, it remains a strong, strong return and the decrease in return on capital employed is the result of the new assets related to the new fulfillment center in Varberg. And then finally, in terms of numbers, let's look at the net debt and the net cash position.
At the end of March, we had a net cash position of 105 million Swedish Kronor. The increase in cash compared to a year ago was the result of strong underlying operating cash flow, as well as limited investments in Q1 2026.